Avid Bioservices Inc (CDMO)

[biopharm]

Dr. Robert Califf knows of PS Targeting ? Part I

Evolution of adverse changes in stored RBCs
2007

Elliott Bennett-Guerrero*, Tim H. Veldman†,
Allan Doctor‡,
Marilyn J. Telen§,
Thomas L. Ortel§,
T. Scott Reid†¶,
Melissa A. Mulherin§,
Hongmei Zhu§,
Raymond D. Buck
,
Robert M. Califf**, and
Timothy J. McMahon§††‡‡

Departments of *Anesthesiology and §Medicine and **Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710; †NITROX LLC, Durham, NC 27701; ‡Pediatric Critical Care, Washington University, St. Louis, MO 63110; ¶Cato Research Ltd., Durham, NC 27713;
School of Nursing, University of North Carolina, Greensboro, NC 27402; and ††Durham Veterans Affairs Medical Center, Durham, NC 27705

Communicated by Irwin Fridovich, Duke University Medical Center, Durham, NC, August 28, 2007 (received for review June 13, 2007)

Recent studies have underscored questions about the balance of risk
and benefit of RBC transfusion. A better understanding of the nature
and timing of molecular and functional changes in stored RBCs may
provide strategies to improve the balance of benefit and risk of RBC
transfusion.
..
..
http://www.pnas.org/content/104/43/17063.full.pdf

Now, we have much research in "STORED RBC's = Red Blood Cells" above by Dr. Robert Califf and below some ties to Phosphatidylserine so here is just the beginnings of saying Robert Califf knows what IMPACT that PS Targeting will have upon Big Pharma $$$ profits

-----------------------------------------------

Phosphatidylserine exposure on stored red blood cells as a parameter for donor-dependent variation in product quality

2014

Sip Dinkla,1 Malou Peppelman,1 Jori van der Raadt,1 Femke Atsma,2 Vera M.J. Novotný,3 Marian G.J. van Kraaij,4 Irma Joosten,1 and Giel J.C.G.M. Bosman5
1Department of Laboratory Medicine - Laboratory of Medical Immunology, Radboud University Medical Centre, Nijmegen Institute for Infection Inflammation and Immunity, Nijmegen, The Netherlands
2Department of Donor Studies, Sanquin Research, Nijmegen, The Netherlands
3Department of Hematology, Radboud University Medical Centre, Nijmegen Institute for Infection Inflammation and Immunity, Nijmegen, The Netherlands
4Unit Medical Affairs, Sanquin Blood Bank Southeast Region, Nijmegen, The Netherlands
5Department of Biochemistry, Radboud University Medical Centre, Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands

Abstract
Background

Exposure of phosphatidylserine on the outside of red blood cells contributes to recognition and removal of old and damaged cells. The fraction of phosphatidylserine-exposing red blood cells varies between donors, and increases in red blood cell concentrates during storage. The susceptibility of red blood cells to stress-induced phosphatidylserine exposure increases with storage. Phosphatidylserine exposure may, therefore, constitute a link between donor variation and the quality of red blood cell concentrates.
..
...
Discussion

The fraction of phosphatidylserine-exposing red blood cells is a parameter of red blood cell integrity in red blood cell concentrates and may be an indicator of red blood cell survival after transfusion. Measurement of phosphatidylserine exposure may be useful in the selection of donors and red blood cell concentrates for specific groups of patients.
..
..
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039702/

So now I ask, what the hell was Dr. Satish Chandran doing in North Dakota and why did he leave Pfizer for the cold of North Dakota en route to Florida and what exactly did he learn ?? since he

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=91695570

--------------

Somahlution is currently developing products to address unmet clinical needs such as those challenges associated with successful heart transplantation, through the use of non-beating hearts, supporting longer storage times, improving quality of the organ and preventing IRI post transplantation. To learn more about Somahlution’s pipeline,

http://somahlution.com/medical-professionals/organ-transplantation/heart-transplantation

-------------

Jupiter biotech company hires dozens, more growth planned
Feb 10, 2014

Satish Chandran’s move from frigid Fargo, North Dakota down to Jupiter has resulted in dozens of biotech jobs and he may only be getting started.

A former researcher at Pfizer, Chandran started building a biopharmaceutical center at North Dakota State University in 2010 and the same year he teamed with Scranton, Pa. neurologist and biotech entrepreneur Vithal Dhaduk to co-found Somahlution. The company was based on technologies to improve organ transplant proceedures.

http://www.bizjournals.com/southflorida/news/2014/02/10/jupiter-biotech-company-hires-dozens.html

------------------------------

Sounds fishy to me that Dr. Chandran is at the heart of the sabotage in North Dakota possibly, and now after what we are learning about storage of red blood cells..etc, he all of a sudden has a solution to allow organs to last longer for transplants..etc..etc ? I wonder if some PS Targeting was involved ??

I think ...yes